Paroxysmal dyskinesias (PxD) refer to a rare group of clinically and genetically heterogeneous disorders presenting with recurrent attacks of abnormal movements, typically dystonia, chorea or a combination thereof, without loss of consciousness.
Introduction
Paroxysmal dyskinesias (PxD) are a group of heterogeneous syndromes that characteristically manifest with recurrent attacks of abnormal movements, typically dystonia, chorea or a combination thereof, without loss of consciousness 1 .
Considering the etymology and literal meaning of the words "paroxysmal" and "dyskinesia", one would realize that neither term is specific enough to unequivocally identify the entities that are classically referred to as PxD. The term "paroxysmal",
(from Greek paroxusmós -irritation, the severe fit of a disease) refers to sudden attack, recurrence, or intensification of a disease 2 . According to this definition, even waxingand-waning conditions like tic syndromes or movement disorders that appear or worsen on action (action-myoclonus or action-tremor for instance) would fit into this category.
The term dyskinesia (from Greek, dys + kinesis, altered movement) is also used in the medical literature with different meanings. Some medical dictionaries propose that it should be used to indicate an impairment of the ability to execute voluntary movements 3 , whereas others emphasize the hyper-kinetic nature of the disorder and suggest that dyskinesias are involuntary jerky or slow writhing movements, often of a fixed pattern, including tics, myoclonus, chorea and dystonia 4 .
It appears clear that such definitions are too broad and do not match with the meaning that movement disorder experts give to the term "paroxysmal dyskinesias". This calls for the need for a clear definition of what should be intended as PxD, to avoid further ambiguity in the literature.
Moreover, increasing knowledge regarding the possible aetiologies underlying the PxD has challenged the concept they could represent distinct disease entities (i.e., that one phenotype could be only attributable to one single aetiology) [5] [6] [7] . Hence, following a brief overview of the historical aspects and the classification of PxD based on triggers (see below), a further in-depth section will be structured according to the different aetiologies that produce PxD. This section will cover novel genetic disorders that might encompass in their phenotype paroxysmal dystonia and/or chorea, but escape the current classification of PxD.
A final section is meant to provide a diagnostic strategy to deal with PxD. This framework emphasizes that these diagnostic labels represent clinical syndromes (and not disease entities), provides criteria for case-definition, and endorses the approach recently used for dystonia in general 8 (i.e., isolated versus combined PxD, thereby discarding the former criterion requiring normal neurological examination between the attacks). On the basis of different clinical features including, but not limited to, triggers, appropriate investigations are suggested to reach a definite diagnosis, upon which treatment is heavily dependent. It is not in the aims of the current paper to review the pathophysiological mechanisms underpinning this group of disorders and the interested readers are referred elsewhere 9 . The search strategy is detailed in box 1.
BOX 1

Search strategy and selection criteria
References for this Review were identified by searches of PubMed, EMBASE and Google Scholar, between 1940 and January 2018, and references from both relevant articles and book chapters. The search terms "paroxysmal dyskinesias", "paroxysmal dystonia", "PRRT2", "MR-1", "SCL2A1", "GLUT1", "KNCMA1", "ADCY5", "ATP1A3", "PKD", "PNKD", and "PED" were used. There were no language restrictions. The final reference list was generated on the basis of relevance to the topics covered in this Review.
Historical definition and classification of paroxysmal dyskinesias
Between 1940 and 1977, three main forms of episodic movement disorders were recognized [10] [11] [12] and classified based on the duration of attacks 12 . Following this earlier classification 12 , a subsequent proposal by Demirkiran and Jankovic discarded the duration of attacks as informative and focused on the difference between triggers 13 .
They recognized three subtypes, encompassing paroxysmal kinesigenic (PKD), nonkinesigenic (PNKD), and exercise-induced (PED) dyskinesias 13 . The term dyskinesia was privileged over others previously adopted because the specific phenomenology of the attacks (i.e., dystonia vs chorea) could only be presumed based on patients' description. A fourth subtype was also proposed [i.e. paroxysmal hypnogenic dyskinesias (PHD) characterized by attacks occurring during sleep without identifiable trigger] 13 , but this entity has been subsequently suggested to be a form of autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE) in most cases 14 .
Each of these forms could be further stratified into primary and secondary disorders 13 .
However, the term "primary" is increasingly dismissed as it carries the implication that there is absence of detectable abnormalities 15 , whereas most primary PxD are in fact found to be secondary to a genetic defect. Moreover, it was suggested that patients with secondary PxD have inter-ictal signs reflecting the underlying disorder 13 , as opposed to cases with primary PxD. However, as anticipated above and discussed in detail below, many patients with "primary" genetic forms of PxD do have inter-ictal findings on examination. One example is represented by SLC2A1 (GLUT-1) mutations, which can produce isolated PED (previously assigned the DYT18 number)spasticity (previously assigned the DYT9 number) 17 as well as a number of other different phenotypes.
Disorders presenting with paroxysmal dyskinesias
PRRT2
In 
SLC2A1
Mutations in SLC2A1 encoding the glucose transporter type 1 (GLUT1) have been discovered to cause a spectrum of neurological phenotypes, including PED 5,9,14-16 . The latter is characterized by attacks of chorea and dystonia affecting mainly the lower limbs that are typically triggered by sustained exercise 5, 9, [14] [15] [16] 25 . There is some phenotype-genotype correlation, with splice site, nonsense, insertions or deletions leading to loss of function SLC2A1 mutations being associated with younger age at onset and a more severe clinical phenotype of GLUT1 deficiency syndrome, including epilepsy, hypotonia, spasticity, ataxia, and developmental delay 14, 25 . This compares with missense SLC2A1 mutations, which more commonly present with PED in older patients S11 , the age at onset ranging from 1 to 50 years of age. As such, depending on the specific underlying genetic defect, PED can manifest as an isolated syndrome (about one-third of SLC2A1 cases) or be associated with other neurological disorders 25,S11 . Most cases with PED are de-novo, whereas only 10% have a positive family history 15, 16 . Although autosomal recessive transmission has been described in rare cases of GLUT1 deficiency syndrome S12 , this has not been reported in patients with PED. It is important to remark that while PED is the most common type of PxD reported in SLC2A1 cases, other non-kinesigenic triggers have also been described 14 and patients can manifest other episodic neurological disorders including episodic ataxia 5,S13 .
PxD in the context of SLC2A1 cases have a positive but partial response to a ketogenic diet 26 , which should be pursued to treat the underlying neuroglycopenia.
KNCMA1
Mutations in KNCMA1, which encodes for a subunit of a calcium-activated potassium channel, have been reported in 2005 to cause a syndrome of PNKD and epilepsy 27 .
Clinically, the PxD borne resemblance with the non-kinesigenic variant and alcohol was noted as a possible (but not constant) trigger 27 . Two additional PNKD patients with KCNMA1 mutations have been subsequently reported to lack epilepsy, but they presented with neurodevelopmental delay S14 . As such, at variance from MR-1 patients, KCNMA1 mutations cause PNKD associated with either epilepsy or neurodevelopmental delay. PNKD in KNCMA1 carriers variably respond to antiepileptic drugs 27,S14 .
ECHS1
ECHS1 encodes for the short-chain enoyl-CoA hydratase protein, mutations of which have been reported as a cause of early-onset Leigh syndrome (or a Leigh-like syndrome with atypical, often milder form with later onset) S15 . ECHS1 mutations have been further associated with PxD, which can be either isolated or combined with a number of features suggestive of a mitochondrial disease 28-30,S15 . Thus, ECHS1 mutations have been associated with intermittent episodes of long-duration (30-50 min) opisthotonus with no identifiable trigger S15 , but also with episodes of dystonia clearly induced by sustained exercise 29, 30 . Although a previous report has labelled the latter episodes as "kinesigenic" 28 , a careful analysis of the original case description reveals that the attacks were actually triggered by "physical strain" 28 . Two more recent reports have confirmed that PxD due to ECHS1 mutations are more likely to be in the form of PED, with or without normal inter-ictal neurological examination 29, 30 .
It is worthy of note that all patients described so far have pallidal hyperintensity on T2- .
The paroxysmal dystonia might be brought on by prolonged exercise, thus meeting the criteria for PED, or without any clear trigger, thus falling into the PNKD category 31,32,S17,S18 . Attacks are sometimes reported to be hemi-dystonic. Similar attacks have been reported in patients with PDHX and DLAT mutations 32,S16,S18 acknowledging that the latter two conditions are far less common than PDHA1 mutations.
Raised (serum or CSF) lactate and/or pyruvate levels along with pallidal hyperintensity suggesting striatal necrosis are important clues to suspect PDC deficiency mutations S16-S18 , but it is important to recognize that these might be lacking and, therefore, this condition should be considered in the differential diagnosis of isolated PED/PNKD even in the absence of any detectable biochemical or imaging abnormality, as it is a treatable condition that responds to thiamine supplementation S19 . In other cases, beneficial outcomes have been also reported with a ketogenic diet S17 , which supports energy failure as the main pathophysiological mechanism for the PxD occurring in the context of PDC deficiency.
GCH1
GCH1 codes for the GTP cyclohydrolase I, a rate limiting enzyme in the synthesis of tetrahydrobiopterin from GTP, mutations of which account for about 50% of doparesponsive dystonias. A few patients with GCH1 mutations have been described with a phenotype consistent with PED. In 2010, Dale and colleagues described a family with two affected members with isolated PED 33 . Attack duration was about 5 minutes and they never occurred at rest or during movement initiation 33 . Moreover, Erro et al. found
was that of dystonia and attacks were localized to the lower limbs 34 . As expected, patients had a dramatic benefit upon levodopa supplementation 34 .
SCN8A
Recently mutations in SCN8A, which encodes for sodium voltage-gated channel alpha subunit 8, have been suggested to be an alternative cause of the ICCA syndrome (i.e., PKD and infantile convulsions) in one recent report 35 . However, this proposal has been subsequently questioned S20 based on the evidence that, in one affected case, a "PKD"
spell was recorded by video-EEG and a cortical signal was documented, suggesting that such attacks might in fact be epileptic in nature. Therefore, it is unclear whether mutations in this gene truly cause PKD or not. However, it has to be acknowledged that in other reports SCN8A mutations have been associated with episodic dystonia, although the term paroxysmal dyskinesia was not explicitly used 36 . As such, it is worth considering this condition in the differential diagnosis of PxD, especially when associated with epileptic seizures, particularly those refractory to antiepileptic therapy, and/or with neurodevelopmental delay 36 .
ADCY5
Mutations in ADCY5, which encodes for the adenylate cyclase 5, have been reported to cause a spectrum of (non-paroxysmal) movement disorders ranging from dystonia to chorea, sometimes associated with axial hypotonia and PxD Characteristically, there is a rostrocaudal gradient in the hemiplegic/hemi-dystonic episodes (face/neck>arm>leg) 41,42,S24 , which can aid the differentiation from other types of hemi-dystonic attacks. Hemiplegic and hemi-dystonic episodes typically shift from one side of the body to the other and typically disappear falling asleep 41,42,S24 .
Almost invariably the hemi-dystonic attacks are combined with other (inter-ictal)
features such as developmental impairment, walking difficulties/ataxia, muscular hypotonia, dysarthria and choreoathetosis. The mainstay of treatment is flunarizine (10-20 mg/day) as a prophylactic drug along with avoiding trigger situations 41,42,S24 .
Patients should be encouraged to sleep when attacks begin, using fast-acting benzodiazepines if necessary.
CACNA1A
Mutations in the CACNA1A gene, which encodes for the calcium voltage-gated channel subunit alpha1 A, are associated with a number of phenotypes including SCA6, episodic ataxia type 2 as well as familial hemiplegic migraine S25 . In a minority of cases, CACNA1A mutations have been suggested to account for some cases of paroxysmal benign torticollis of infancy (BPTI) 43, 44 . It is characterized by episodes of head tilt with onset within the first 18 months of life that usually resolve by age 5 43, 44 . The attack duration ranges from 10 minutes to several days and are frequently accompanied vomiting, pallor, and ataxia 43, 44 . BPTI usually resolves after infancy, but can be replaced by paroxysmal vertigo and/or migraine 43, 44 . The co-occurrence of episodic ataxia, hemiplegic migraine and paroxysmal tonic upgaze in a single subject or in the family make mutations in this gene more likely 45 . This condition is self-limiting and usually no treatment is required.
SLC16A2
SLC16A2 encodes for the monocarboxylate transporter type 8 (MCT8), which is required for trans-membrane uptake of free triiodothyronine (fT3) from blood into neurons. MCT8 deficiency results in a complex, X-linked disorder (also known as Allan-Herndon-Dudley syndrome) characterized by proximal hypotonia with poor head control, generalized muscular hypotrophy, microcephaly and marked developmental delay 46 .
The disorder is progressive and spasticity, ataxia, and severe dysarthria complicate the clinical phenotype. In a subset of patients, a specific sort of PKD is observed 46, 47 .
Attacks are in fact classically triggered by passive movements such as changing of their clothes or nappies or by lifting the children from one place to another 46, 47 . However, attacks can also be triggered by excitement, happiness or crying 46, 47 . Attacks are brief, lasting seconds to few minutes, and are dystonic in nature 46, 47 . The hallmark of MCT8 deficiency is raised serum concentration of fT3 46 . . The fact that all affected members shared the phenotype of isolated PxD with normal inter-ictal examination S48,S49 might support the idea that PxD are intrinsically associated with these mutations rather than being merely secondary to basal ganglia calcification, as assumed in earlier reports of the pre-genetic era S49 . This, however, remains speculative, but it further exemplifies the ambiguity regarding the concept of primary and secondary PxD.
Other causes of paroxysmal dyskinesias
In general, PxD due to acquired, immunological or neurodegenerative causes, present usually at a later age compared to the main genetic forms reviewed above and manifest with additional signs or symptoms that will easily drive the diagnostic work-up and lead to the correct diagnosis and appropriate management in most cases.
Recently, DEPDC5 S10 and CHRNA4 49 mutations have been associated with the syndrome of PKD plus epilepsy in single families. However, these two genes are also a cause of ADNFLEdystonia are epileptic in nature or not. Moreover, these results require replication before screening of these genes might be recommended in clinical practice.
Immune-mediated disorders
Multiple sclerosis 48 Moreover, we support the concept of PxD occurring during sleep as a further triggerbased subtype. Although sleep is not strictly a trigger, it can be considered equivalent to other triggers since they all give an answer to the question of when PxD occur (i.e., after sudden movements, after alcohol/caffeine ingestion, during sleep, etc.).
At variance with former classifications of PxD, we discard the criterion of normal interictal examination. As such, all the aforementioned trigger-based subtypes can be isolated or combined with additional features. This reiterates a previous suggestion proposing the stratification of PxD into "pure" and "complicated" forms 53 , based on the absence or presence of additional inter-ictal neurological signs, respectively. We also advocate this approach for two main reasons. Firstly, there is evidence of clinical heterogeneity for single gene mutations. For instance, PRRT2 and SLC2A1 mutations can produce either isolated or combined PxD. Secondly, we believe the syndromic approach will facilitate the differential diagnosis ( figure 1 ). For instance, the presence of epilepsy in a patient with "classic" PNKD will make the presence of MR-1 mutations very unlikely. Such a syndromic approach would also prioritize some investigations over others. This might be the case for PED in which CSF examination for glucose, pterin pathway components, pyruvate and lactate would provide more information than imaging.
Whenever the attacks lack specific and consistent triggers, have variable duration, and when the onset is in adulthood, "symptomatic" causes (table 2) need to be excluded, especially in the absence of family history. Given the huge variability of symptomatic PxD forms in their clinical presentation, even within the single subject, it is hard identify any phenotypic patterns suggestive of the underlying aetiology. In general, certain findings including painful attacks, fluctuating levels of consciousness, and dysautonomic crises that are not classically seen in the genetic conditions reviewed here, should prompt the clinician to rule out acquired causes. In such cases, an initial diagnostic work up including metabolic and electrolyte panels, investigation for autoimmune disorders, and brain imaging will allow a definitive diagnosis to be determined in most cases.
Conclusions
In recent years, great advances have led to a better understanding of the broad spectrum of genetic conditions underlying the PxD. This has increasingly challenged the former phenomenological classification as well as the idea that any specific phenotypes were associated to single gene mutations. Such an argument reiterates previous proposals 14 that classification of PxD should follow a two-pronged method, according to which both the clinical phenotype and the specific genetic mutation should be stated (PRRT2-PKD for example).
It is worth specifying that our proposal does not represent a classification scheme, but reflects an algorithmic approach to help clinicians in the differential diagnosis. First, it
gives clarity to the definition of PxD. Second, it has the merit of encompassing an increasing number of recently identified conditions with PxD as a feature that would escape the current classification. On the other hand, the phenotypic and genetic heterogeneity of PxD highlighted here might render the test of candidate genes, based on a specific clinical syndrome, unsuccessful. In this context, it might be argued that next-generation sequencing approaches would better apply to the need of a rapid comprehensive genetic screening 54 . This would further reduce costs in comparison to single gene testing 55 .
Of course there will be cases where no definitive cause for PxD can be found and treatment is to be pursued empirically. These can be labelled as idiopathic forms while awaiting for further elucidation of genetic or other causes. In turn, our proposal will require updating as soon as novel evidence is available. 
